Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.

Aiken R, Axelson M, Harmenberg J, Klockare M, Larsson O, Wassberg C.

Oncotarget. 2017 Sep 6;8(46):81501-81510. doi: 10.18632/oncotarget.20662. eCollection 2017 Oct 6.

2.

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J.

Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12. Review.

4.

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.

Bergqvist M, Holgersson G, Bondarenko I, Grechanaya E, Maximovich A, Andor G, Klockare M, Thureson M, Jerling M, Harmenberg J.

Acta Oncol. 2017 Mar;56(3):441-447. doi: 10.1080/0284186X.2016.1253866. Epub 2016 Nov 24.

PMID:
27882820
5.

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J.

Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10.

PMID:
26553306
6.

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

Ekman S, Harmenberg J, Frödin JE, Bergström S, Wassberg C, Eksborg S, Larsson O, Axelson M, Jerling M, Abrahmsen L, Hedlund Å, Alvfors C, Ståhl B, Bergqvist M.

Acta Oncol. 2016;55(2):140-8. doi: 10.3109/0284186X.2015.1049290. Epub 2015 Jul 10.

PMID:
26161618
7.

A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.

Holgersson G, Bergström S, Harmenberg J, Ringbom M, Klockare M, Jerling M, Ekman S, Lundström KL, Koyi H, Brandén E, Larsson O, Bergqvist M.

Med Oncol. 2015 Apr;32(4):129. doi: 10.1007/s12032-015-0578-y. Epub 2015 Mar 21.

PMID:
25794491
8.

Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry.

Rönquist-Nii Y, Eksborg S, Axelson M, Harmenberg J, Ekman S, Bergqvist M, Beck O.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Feb 15;879(5-6):326-34. doi: 10.1016/j.jchromb.2010.12.017. Epub 2010 Dec 28. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 15;889-890:148. Ekman, Simon [added]; Bergqvist, Michael [added].

PMID:
21251888
9.

[Recurrent herpes simplex labialis infections. Possible prevention with a new therapeutic regimen].

Harmenberg J, Spruance S.

Lakartidningen. 2010 Aug 25-31;107(34):1918-22. Review. Swedish. No abstract available.

PMID:
20960953
10.

Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial.

Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, Darpö B, Levin MJ, Tyring S, Spruance SL; ME-609 Study Group.

J Am Acad Dermatol. 2011 Apr;64(4):696.e1-11. doi: 10.1016/j.jaad.2010.08.012. Epub 2010 Sep 20.

PMID:
20851499
11.

Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.

Ekman S, Frödin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, Alvfors C, Ståhl B, Bergström S, Bergqvist M.

Acta Oncol. 2011 Apr;50(3):441-7. doi: 10.3109/0284186X.2010.499370. Epub 2010 Aug 11.

PMID:
20698809
12.

Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: A literature review.

Harmenberg J, Oberg B, Spruance S.

Acta Derm Venereol. 2010 Mar;90(2):122-30. doi: 10.2340/00015555-0806. Review.

13.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS.

Lancet Oncol. 2007 Jul;8(7):587-94.

PMID:
17544845
14.

Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.

Ghosn J, Quinson AM, Sabo N, Cotte L, Piketty C, Dorléacq N, Bravo ML, Mayers D, Harmenberg J, Mårdh G, Valdez H, Katlama C.

HIV Med. 2007 Apr;8(3):142-7.

15.

MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.

Katlama C, Ghosn J, Tubiana R, Wirden M, Valantin MA, Harmenberg J, Mårdh G, Oberg B, Calvez V.

AIDS. 2004 Jun 18;18(9):1299-304.

PMID:
15362662
16.

ME-609: a treatment for recurrent herpes simplex virus infections.

Harmenberg JG, Awan AR, Alenius S, Ståhle L, Erlandsson AC, Lekare G, Flink O, Augustsson E, Larsson T, Wikström AC, Stierna P, Field HJ, Larsson AG, Oberg B.

Antivir Chem Chemother. 2003 Jul;14(4):205-15.

PMID:
14582849
17.

Herpes simplex virus type 1 infection and glucocorticoid treatment regulate viral yield, glucocorticoid receptor and NF-kappaB levels.

Erlandsson AC, Bladh LG, Stierna P, Yucel-Lindberg T, Hammarsten O, Modéer T, Harmenberg J, Wikström AC.

J Endocrinol. 2002 Oct;175(1):165-76.

PMID:
12379500
18.

Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis.

Evans TG, Bernstein DI, Raborn GW, Harmenberg J, Kowalski J, Spruance SL.

Antimicrob Agents Chemother. 2002 Jun;46(6):1870-4.

19.

Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.

Mousavi-Jazi M, Schloss L, Drew WL, Linde A, Miner RC, Harmenberg J, Wahren B, Brytting M.

J Clin Virol. 2001 Dec;23(1-2):1-15.

PMID:
11595579
20.

Limitations of cytomegalovirus testing.

Harmenberg J, Brytting M.

Antimicrob Agents Chemother. 1999 Jun;43(6):1528-9. No abstract available.

21.
22.

Herpes simplex virus zosteriform lesions with adoptive transfer of immune cells: a murine model which mimics human recurrent disease.

Awan AR, Harmenberg J, Kristofferson A, Field HJ.

Antiviral Res. 1998 Apr;38(1):43-53.

PMID:
9614003
24.

G- and GM-CSF in oncology and oncological haematology.

Harmenberg J, Höglund M, Hellström-Lindberg E.

Eur J Haematol Suppl. 1994;55:1-28. Review.

PMID:
7518779
25.
26.

Intermittent rG-CSF treatment in cyclic neutropenia.

Danielsson L, Harmenberg J.

Eur J Haematol. 1992 Feb;48(2):123-4. No abstract available.

PMID:
1372269
27.

Comparison of different tests of fencing performance.

Harmenberg J, Ceci R, Barvestad P, Hjerpe K, Nyström J.

Int J Sports Med. 1991 Dec;12(6):573-6.

PMID:
1797700
28.

The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline.

Harmenberg J, Akesson-Johansson A, Gräslund A, Malmfors T, Bergman J, Wahren B, Akerfeldt S, Lundblad L, Cox S.

Antiviral Res. 1991 Mar-Apr;15(3):193-204.

PMID:
1653556
29.

Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.

Cox S, Koshida R, Harmenberg J, Wahren B.

Adv Enzyme Regul. 1991;31:85-97.

PMID:
1715118
30.

Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds.

Akesson-Johansson A, Harmenberg J, Wahren B, Linde A.

Antimicrob Agents Chemother. 1990 Dec;34(12):2417-9.

31.

Synergistic inhibition of human immunodeficiency virus replication in vitro by combinations of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine.

Harmenberg J, Akesson-Johansson A, Vrang L, Cox S.

AIDS Res Hum Retroviruses. 1990 Oct;6(10):1197-202.

PMID:
1701316
32.
33.

Physiological and morphological characteristics of world class fencers.

Nyström J, Lindwall O, Ceci R, Harmenberg J, Svedenhag J, Ekblom B.

Int J Sports Med. 1990 Apr;11(2):136-9.

PMID:
2338374
34.
35.

Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Koshida R, Vrang L, Gilljam G, Harmenberg J, Oberg B, Wahren B.

Antimicrob Agents Chemother. 1989 May;33(5):778-80.

36.

Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs.

Harmenberg J, Wahren B, Bergman J, Akerfeldt S, Lundblad L.

Antimicrob Agents Chemother. 1988 Nov;32(11):1720-4.

37.

Antiviral activities of guanosine analogs in guinea pig embryonic fibroblasts.

Harmenberg J, Stenberg K.

Antimicrob Agents Chemother. 1988 Oct;32(10):1533-6.

38.
41.

New tools for the herpes virologist.

Harmenberg J, Levén B, Hinkula J, Ohlsson E, Sundqvist V, Wahren B.

Int J Technol Assess Health Care. 1988;4(4):634-6. No abstract available.

PMID:
10314329
43.

Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture.

Abele G, Karlström A, Harmenberg J, Shigeta S, Larsson A, Lindborg B, Wahren B.

Antimicrob Agents Chemother. 1987 Jan;31(1):76-80.

44.

Comparative methods for detection of thymidine kinase-deficient herpes simplex virus type 1 strains.

Harmenberg J, Sundqvist VA, Gadler H, Levén B, Brännström G, Wahren B.

Antimicrob Agents Chemother. 1986 Oct;30(4):570-3.

45.

[New aspects in the diagnosis and treatment of herpes infections].

Heimdahl A, Abele G, Harmenberg J, Zetterqvist L.

Tandlakartidningen. 1986 Sep;78(17):865-9, 871-3. Swedish. No abstract available.

PMID:
3024345
46.

Influence of acyclovir and bucyclovir on nucleotide pools in cells infected with herpes simplex virus type 1.

Karlsson AH, Harmenberg JG, Wahren BE.

Antimicrob Agents Chemother. 1986 May;29(5):821-4.

47.

Deoxythymidine pools of human skin and guinea pig organs.

Harmenberg J, Malm M, Abele G.

FEBS Lett. 1985 Sep 2;188(2):219-21.

48.

Multiplicity dependence and sensitivity of herpes simplex virus isolates to antiviral compounds.

Harmenberg J, Wahren B, Sundqvist VA, Levén B.

J Antimicrob Chemother. 1985 May;15(5):567-73.

PMID:
2989239
49.

Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells.

Harmenberg J, Abele G, Wahren B.

Antiviral Res. 1985 Apr;5(2):75-81.

PMID:
3160302
50.

Pseudouridine and uridine in normal kidney and kidney cancer tissues.

Koshida K, Harmenberg J, Borgström E, Wahren B, Andersson L.

Urol Res. 1985;13(5):219-21.

PMID:
4060365

Supplemental Content

Loading ...
Support Center